tetano
Editor, Senior Moderator
Transplantation
. 2020 Dec 2.
doi: 10.1097/TP.0000000000003524. Online ahead of print.
Development and Validation of a Multiplex, Bead-Based Assay to Detect Antibodies Directed Against SARS-CoV-2 Proteins
Robert A Bray[SUP] 1 [/SUP], Jar-How Lee[SUP] 2 [/SUP], Peter Brescia[SUP] 3 [/SUP], Deepali Kumar[SUP] 4 [/SUP], Thoa Nong[SUP] 3 [/SUP], Remi Shih[SUP] 3 [/SUP], E Steve Woodle[SUP] 5 [/SUP], Jonathan S Maltzman[SUP] 6 [/SUP], Howard M Gebel[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Transplant recipients who develop COVID-19 may be at increased risk for morbidity and mortality. Determining the status of antibodies against SARS-CoV-2 in both candidates and recipients will be important to understand the epidemiology and clinical course of COVID-19 in this population. While there are multiple tests to detect antibodies to SARS-CoV-2, their performance is variable. Tests vary according to their platforms and the antigenic targets which make interpretation of the results challenging. Furthermore, for some assays, sensitivity and specificity is less than optimal. Additionally, currently available serological tests do not exclude the possibility that positive responses are due to cross reactive antibodies to community coronaviruses rather than SARS-CoV-2.
Methods: This study describes the development and validation of a high throughput multiplex antibody detection assay.
Results: The multiplex assay has the capacity to identify, simultaneously, patient responses to 5 SARS-CoV-2 proteins, namely, the full spike protein, 3 individual domains of the spike protein (S1, S2 and receptor binding domain) and the nucleocapsid protein. The antibody response to the above proteins are SARS-CoV-2 specific, as antibodies against 4 common coronaviruses do not cross-react.
Conclusions: This new assay provides a novel tool to interrogate the spectrum of immune responses to SAR-CoV-2 and is uniquely suitable for use in the transplant setting. Test configuration is essentially identical to the single antigen bead assays used in the majority of histocompatibility laboratories around the world and could easily be implemented into routine screening of transplant candidates and recipients.
. 2020 Dec 2.
doi: 10.1097/TP.0000000000003524. Online ahead of print.
Development and Validation of a Multiplex, Bead-Based Assay to Detect Antibodies Directed Against SARS-CoV-2 Proteins
Robert A Bray[SUP] 1 [/SUP], Jar-How Lee[SUP] 2 [/SUP], Peter Brescia[SUP] 3 [/SUP], Deepali Kumar[SUP] 4 [/SUP], Thoa Nong[SUP] 3 [/SUP], Remi Shih[SUP] 3 [/SUP], E Steve Woodle[SUP] 5 [/SUP], Jonathan S Maltzman[SUP] 6 [/SUP], Howard M Gebel[SUP] 1 [/SUP]
Affiliations
- PMID: 33273320
- DOI: 10.1097/TP.0000000000003524
Abstract
Background: Transplant recipients who develop COVID-19 may be at increased risk for morbidity and mortality. Determining the status of antibodies against SARS-CoV-2 in both candidates and recipients will be important to understand the epidemiology and clinical course of COVID-19 in this population. While there are multiple tests to detect antibodies to SARS-CoV-2, their performance is variable. Tests vary according to their platforms and the antigenic targets which make interpretation of the results challenging. Furthermore, for some assays, sensitivity and specificity is less than optimal. Additionally, currently available serological tests do not exclude the possibility that positive responses are due to cross reactive antibodies to community coronaviruses rather than SARS-CoV-2.
Methods: This study describes the development and validation of a high throughput multiplex antibody detection assay.
Results: The multiplex assay has the capacity to identify, simultaneously, patient responses to 5 SARS-CoV-2 proteins, namely, the full spike protein, 3 individual domains of the spike protein (S1, S2 and receptor binding domain) and the nucleocapsid protein. The antibody response to the above proteins are SARS-CoV-2 specific, as antibodies against 4 common coronaviruses do not cross-react.
Conclusions: This new assay provides a novel tool to interrogate the spectrum of immune responses to SAR-CoV-2 and is uniquely suitable for use in the transplant setting. Test configuration is essentially identical to the single antigen bead assays used in the majority of histocompatibility laboratories around the world and could easily be implemented into routine screening of transplant candidates and recipients.